

Figure S1. eIF3c in RCC and adjacent normal tissues were detected by reverse transcription-quantitative PCR. GAPDH was used as an internal control. n=9, **P<0.01. eIF3c, eukaryotic initiation factor 3c; RCC, renal cell carcinoma.




Table SI. Signaling pathways involved in the eIFs family.

Author, year	Name	Pathway	Research field	(Refs.)
Lee <i>et al</i> , 2018	eIF3c	S100A11	Hepatocellular carcinoma	(25)
Zhao <i>et al</i> , 2017	eIF3c	mTOR	Breast cancer	(26)
Shen <i>et al</i> , 2014	eIF3a	p27	Non-small cell lung cancer	(39)
Xu <i>et al</i> , 2016	eIF3b	β -catenin	Esophageal squamous cell carcinoma	(40)
Zhu <i>et al</i> , 2016	eIF3h	Growth factor- β , MAPKs	Hepatocellular carcinoma	(41)
Qi <i>et al</i> , 2014	eIF3i	PTGS2, β -catenin	Colorectal cancer	(42)
Golob-Schwarzl <i>et al</i> , 2017	eIF1, eIF5, eIF6	PI3K/Akt/mTOR	Colorectal cancer	(43)
Zang <i>et al</i> , 2017	eIF3b	Akt	Renal cell carcinoma	(37)
Chen <i>et al</i> , 2016	eIF4b	PI3K/Akt/mTOR	Leukemia	(44)
Deng <i>et al</i> , 2004	eIF2	NF- κ B	Fibroblast	(45)

eIFs, eukaryotic initiation factors; PTGS2, prostaglandin-endoperoxide synthase 2.